Zai Lab Limited is a commercial-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies for oncology, immunology, neuroscience, and infectious disease. The company operates in Greater China and the United States, maintaining a substantial presence in both regions. Its commercial portfolio includes ZEJULA, VYVGART, NUZYRA, OPTUNE, QINLOCK, XACDURO, and AUGTYRO, which have received marketing approval in Greater China. Zai Lab conducts in-house drug discovery for small molecules and biologics, supported by manufacturing facilities in Suzhou for both small-molecule and large-molecule production. The company partners with global biopharmaceutical firms to expand its pipeline, which includes candidates such as zocilurtatug pelitecan for small cell lung cancer and efgartigimod for autoimmune conditions. Founded in 2014 by Dr. Samantha Du, Zai Lab integrates research, clinical development, and commercialization to address unmet medical needs.

Summarised from the company's own disclosures, fiscal year ended Apr 2026

Industry Biotechnology Homepage zailaboratory.com
Sector Healthcare IR page ir.zailaboratory.com
Tags
oncology, immunology, neuroscience, infectious disease, antibody-drug conjugates, small molecules, biologics, clinical development, commercialization, ZEJULA, VYVGART, VYVGART Hytrulo, NUZYRA, OPTUNE, QINLOCK, XACDURO, AUGTYRO, zocilurtatug pelitecan, ZL-1310, ZL-1503, ZL-6201, efgartigimod alfa, tisotumab vedotin, repotrectinib, xanomeline and trospium chloride, TIVDAK, COBENFY, argenx
Press page —

Metrics

Valuation  
Market cap HK$ 21.83B
Market cap (USD) $ 2.782B
P/E -14.78
PEG —
P/BV 4.15
P/S 6.19
P/OCF -20.86
P/FCF —
Dividend yield —
Turnover / mcap 0.26%
Returns  
ROE -22.6%
ROI -24.5%
ROIC -24.0%
Profit margin -38.1%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 4
Quality score -23.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018
Revenue 460.156M 398.988M 266.719M 215.04M 144.312M 48.958M 12.985M 129K
Net profit -175.537M -257.103M -334.62M -443.286M -704.471M -268.905M -195.071M -139.075M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018
Share price 1.88 3.37 0.33 2.98 6.7 13.89 — —
Price performance 12m -0.44 9.05 -0.89 -0.55 -0.52 — — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

GRANT OF SHARE OPTIONS AND RESTRICTED SHARE UNITS Bull 0 Bear 0 Routine
OVERSEAS REGULATORY ANNOUNCEMENT - FORM 10-Q Bull 0 Bear 0 Routine

Prompts

ZAI Lab Limited (ticker 9688), listed in Hong Kong.

ETFs Holding ZAI Lab Limited

ETF Weight in ETF Shares Market value As of
CANC 1.95% 161,278 $ 4.106M Aug 31, 2026
FMED 0.75% 15,273 $ 388.851K Aug 31, 2026
DFEM 0.01% 494,200 $ 1.324M Nov 12, 2026
NTSE 0.01% 425 $ 8,075.00 Jun 30, 2026
DFAE 0.01% 427,500 $ 1.146M Nov 12, 2026
DFAX 0.00% 217,300 $ 582.263K Nov 12, 2026

Securities

Ticker Type Class Market Exchange Last price Price date
ZLAB Common share — US nasdaq 27.19 USD 2026-11-10
9688 canonical Common share — HK hkex 17.35 HKD 2026-11-19